与COVID-19疫苗相关的运动障碍:系统性审查
Grace Elysse D Angeles1, Lowrence Precious C Dichoso1, Roland Dominic G Jamora1,2
1Division of Adult Neurology, Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Journal of movement disorders
|March 19, 2024
概括
接种COVID-19疫苗后的运动障碍是罕见的,但已有报道. 这项系统性审查发现,大多数患有疫苗相关运动障碍的患者,如心肌病,对免疫疗法反应良好.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 在2019年新冠肺炎 (COVID-19) 疫苗接种后,已经报告了神经系统并发症.
- 运动障碍是疫苗接种后的潜在,尽管很少记录的不良事件.
研究的目的:
- 对与COVID-19疫苗相关的运动障碍进行描述性的系统审查.
- 分析患有疫苗相关运动障碍的患者的临床特征,管理和结果.
主要方法:
- 系统性审查已发表的文献,遵守系统性审查和元分析 (PRISMA) 准则的首选报告项目.
- 包括8篇详细介绍10名COVID-19疫苗接种后运动障碍患者的文章.
- 使用标准化工具评估案例质量和偏见风险.
主要成果:
- 在接种COVID-19疫苗后,发现了10例运动障碍病例.
- 观察到的占主导地位的运动障碍是 Hemichorea,其他病例呈现出泛化胆 ?? , dystonia 和 akathisia.
- 大多数受影响的患者 (80%) 是男性,平均年龄为64.5岁. 大多数患者对免疫疗法产生了积极反应,研究通常具有偏差风险较低.
结论:
- 疫苗相关运动障碍的发生率似乎很低,基于有限的公布病例数量.
- 免疫疗法是疫苗相关运动障碍的有效治疗方式.
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K


